抄録
This paper deals with the results of 27 cases (16 myelogenous, 5 monocytic, 5 lymphogenous and 1 case with erythroleukemia) of acute leukemia with a new anti-leukemic agent “Neocarzinostatin”. It was administered alone in 14 cases, concomitantly with prednisolone 10∼80 mg/day in 9 cases and with prednisolone, 6 MP 100 mg/day and cyclocytidine 300∼500 mg/day in 4 cases. A course of Neocarzinostatin administration was 0.04∼0.06 mg/kg/day daily for 2∼5 days by intravenous perfusion.
A complete remission was obtained in 7 of 14 cases (50.0%) treated with Neocarzinostatin alone, 2 of 9 cases (22.2%) treated with Neocarzinostatin and prednisolone and 1 of 4 cases (25.0%) treated with Neocarzinostatin, prednisolone, 6 MP and cyclocytidine.
It is noteworthy that the treatment of Neocarzinostatin alone or combination with prednisolone induced a complete remission in 5 of 8 cases (62.5%) in the groupe of age over 50 year old. A potent leukemocidal effect was proved in most of all cases which have not been induced a remission. Clinically Neocarzinostatin had no cross-resistance with 6 MP and prednisolone.
Side effect of Neocarzinostatin such as nausea and vomiting was not so severe to stop the drug. The degree of myelosupression with Neocarzinostatin was severe, but it was mild when the dosage was reduced to 0.04 mg/kg/day.
From these data Neocarzinostatin was considered to be a new excellent antileukemic agent.
